Articles tagged with Tumor Cells
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
Researchers at University of California - San Francisco have developed a new therapy that overcomes cancer cell barriers and marks them for destruction by the immune system. By pulling mutated KRAS protein to the surface, the drug acts as an “eat me” flag, allowing immunotherapy to eliminate all cells bearing this flag.
Bladder cancer researchers discovered a subset of CD8 T cells that adapts to tumor evasion strategies, offering a strategy to reduce tumor cells' ability to fight them off. The study also identified potential ways to make immunotherapy more effective against this deadly cancer by targeting the HLA-E/NKG2A axis.
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
Researchers have identified fascin as a key player in promoting cancer development, with the protein controlling cell movement and invasion. Forcing fascin into the nucleus of cancer cells could prevent their growth and movement.
Researchers at LSU Health New Orleans have identified a critical immunosuppressive pathway and developed an experimental inhibitor to protect T-cells from weakening. The CBL-B inhibitors show great potential in enhancing the efficacy of cancer immunotherapy, making patients' T-cells more effective in killing cancer cells.
A University of Houston engineer has developed technology to determine which patients are likely to respond to CAR T-cell therapy for lymphoma, saving time and increasing success rates. The TIMING method analyzes interactions between T cells and tumor cells, identifying a key ligand molecule that predicts patient response.
Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.
Scientists have developed a smart contact lens that can capture and detect exosomes, nanometer-sized vesicles found in bodily secretions, which hold promise for cancer diagnostics. The lens was designed to bind to antibodies capturing exosomes found in tears, offering a potential platform for non-invasive cancer screening.
Researchers have identified key molecular differences between cancer cells that cling to initial tumors and those that spread to distant sites. The study found unique properties in cells that gain migratory ability and survival advantages, leading to the development of new treatment targets.
Researchers at the University of Pittsburgh have discovered that even terminally exhausted T cells retain some capacity to function again. They identified approaches to overcome exhaustion by targeting co-stimulation pathways and reprogramming T cells to be resistant to hypoxia, a common tumor microenvironmental signal.
Researchers at Dartmouth Cancer Center developed a new approach for detecting and quantifying tumor heterogeneity in breast cancer. High levels of heterogeneity are linked to poor patient outcomes, while specific proteins regulate its extent. The study aims to utilize this approach in therapeutic decision-making.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
Researchers discovered that liver cancer cells modify their metabolism to leave them susceptible to disruptions in arginine supply, a key molecule. A three-pronged approach targeting tumor metabolism, blocking survival-promoting responses, and starving tumors of arginine can induce senescence, making cancer cells killable.
Researchers at TIBI developed a minimally invasive method for targeted delivery of immunotherapeutic treatments, resulting in slower tumor growth and higher activation of T-cells. The injectable gelatin biomaterial containing silicate nanoplatelets showed sustained drug release and controlled ICI delivery.
Leukemia cells exploit metabolic pathways to evade programmed cell death, but researchers identified a weak spot in acute lymphoblastic leukemia that can be targeted with experimental drugs. Inhibiting glutathione metabolism induces ferroptosis, leading to the death of malignant lymphocytes.
Researchers created a novel tumor organoid system to examine the impact of bacterial metabolites on immune checkpoint blockage, a promising cancer treatment. The system showed that certain bacterial-released factors improved immune cell viability and increased treatment efficacy.
Osaka University researchers identified medullary thymic epithelial cells (mTECs) expressing neuromuscular molecules in myasthenia gravis-thymoma samples. These findings suggest a new connection between the two diseases and may lead to novel therapeutic methods.
A team of researchers has discovered that malignant tumors accumulate lipid delivery molecules called LDL and attract immune suppressor cells called neutrophils, leading to tumor progression. The study also shows that targeting the LOX-1/oxidized LDL axis may be a promising strategy for treating both cancer and cardiovascular disease.
Researchers at Max Delbrück Center for Molecular Medicine found that silencing the EBAG9 gene in CAR T cells increases their effectiveness and reduces side effects. This breakthrough could lead to a new therapy approach for blood cancer patients.
Researchers at Cold Spring Harbor Laboratory have developed a rapid organoid screening test that can predict response to neoadjuvant chemotherapy in pancreatic cancer patients. This test may help optimize personalized treatment plans and improve patient outcomes.
Scientists at the University of Nottingham have developed a new dressing that can prevent the recurrence of melanoma by killing cancer cells while promoting healthy cell growth. The dressing is made with graphene oxide, elastin, and ethanol, and requires only 15 seconds of Near Infrared light every 48 hours to be effective.
Researchers have uncovered how tissue stiffness determines cell positioning and regulates cell migration in various types of cancer, including brain tumors and breast cancer. The study provides new possibilities for stopping and directing cancer cell migration.
A new study by University of Cambridge researchers found that male dogs are four to five times more likely than female dogs to be infected with the oro-nasal form of Canine Transmissible Venereal Tumour. This unusual cancer is infectious and can spread between dogs through contact, commonly affecting genitals but also the nose and mouth.
Researchers have found that tumor cells co-exist with normal tissue in a complex, heterogeneous mixture, leading to unexpected effects on therapeutic resistance. The study suggests that understanding these ecological interactions could lead to novel treatment strategies and improved patient outcomes.
Researchers found that tumour stem cells with Mex3a protein activity remain in a latent state, conferring resistance to chemotherapy. After treatment, these cells are reactivated, leading to cancer relapse. Removing the Mex3a gene makes colorectal cancer cells highly sensitive to chemotherapy.
Research from RCSI University of Medicine and Health Sciences found a link between high von Willebrand Factor levels and poorer breast cancer outcomes. High levels in the bloodstream can increase the risk of life-threatening blood clots and cancer spread in patients.
Researchers will develop and test new beacon molecules and imaging equipment to improve the detection and removal of non-small-cell lung cancers, aiming to reduce unnecessary tissue removal. The goal is to enhance surgical outcomes and improve patient care.
A study by Michigan Medicine researchers has identified oncostreams, highly active cells connected to brain tumor growth and invasion. The team found that eliminating Collagen 1 production from tumor cells reduces tumor aggressive behavior. This discovery could lead to novel therapeutic targets for treating lethal brain tumors.
Researchers at the Netherlands Cancer Institute discovered that prostate cancer cells hijack the circadian rhythm to become resistant to hormone therapy. The study found that proteins regulating the circadian clock play a crucial role in tumor cell survival, offering a potential target for new treatment strategies.
Scientists have created new fluorescent chemical compounds for photodynamic therapy of cancerous tumors, which can stain affected tissues and destroy tumor cells without harm to healthy ones. The compound containing pyrene shows the highest fluorescent and anticancer activity.
A new study from Karolinska Institutet has identified a key mechanism behind treatment resistance in a deadly form of kidney cancer. By increasing mitochondrial content in cancer cells, researchers found that these cells became susceptible to the cancer drug sorafenib. This breakthrough offers hope for more targeted cancer treatments.
Researchers have discovered a protein produced by soft-tissue sarcoma tumors that changes the biology of surrounding immune cells, promoting tumor growth. The study could lead to improved treatments for this rare and aggressive cancer type.
Researchers at Kyoto University identified the mechanism behind active inflammation and immunosuppression in tumor microenvironments. EP2/EP4 inhibitors suppress tumor growth by allowing regulatory T cells to infiltrate and activate within tumors, benefiting patients with certain cancers.
Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.
Researchers developed a mathematical technique to measure total tumor-specific mRNA levels from bulk tumor sequencing data, associating higher mRNA levels with reduced patient survival. The study suggests this approach could serve as a prognostic biomarker for various cancers, guiding treatment selection.
Scientists at Max Delbrück Center identify EBAG9 gene as key inhibitor of T cell function against tumors, releasing the brake and boosting immune response. The discovery aims to develop CAR T cells without EBAG9 for more effective leukemia treatments.
A new machine learning algorithm called 'ikarus' has found a gene signature characteristic of tumors, distinguishing between healthy and tumor cells in various types of cancer. The algorithm was trained on single-cell sequencing data sets and demonstrated an extraordinarily high success rate in distinguishing between different cell types.
Researchers have reported encouraging early-stage data for the Phase 1 clinical trial of INB-200, a gamma-delta T cell-based immunotherapy. All patients enrolled in the trial have exceeded their expected progression-free survival, with two patients exceeding overall survival as well. The treatment shows promising activity against gliob...
Researchers found that 'killer' T-cells used in immunotherapy can also destroy tumour lymphatic vessels, greatly reducing the risk of metastasis. This synergistic effect could increase treatment effectiveness against cancers with high lymphangiogenesis.
A new study led by Cedars-Sinai research suggests that androgen hormones interfere with the body's ability to fight bladder cancer, explaining why males experience higher cancer rates. Androgen deprivation therapy may improve treatment outcomes for male patients.
Researchers led by Atsuo Sasaki aim to identify mechanisms behind cell movement and energy allocation in cancer cells, with potential applications beyond cancer treatment. They will use scanning ion-conductance microscopy and machine learning technology to study the role of GTP in cellular migration.
Researchers from China have developed a novel bioconjugate that can suppress the growth of K-Ras mutant pancreatic tumors. The conjugate, which targets folate receptors and macropinocytosis, was found to be highly cytotoxic and effective at suppressing tumor growth.
New research reveals that age-induced changes in lung fibroblasts reactivate dormant melanoma cells, promoting growth and metastasis. The study found that WNT5A signaling pathway regulates tumor cell dormancy and metastasis initiation, with increased sFRP1 secretion facilitating reactivation in the aged lung.
Researchers at the University of Chicago's Pritzker School of Molecular Engineering have developed a version of interleukin-12 that is activated only when it reaches a tumor, reducing side effects. The new 'masked' molecule has shown promising results in eliminating cancer cells and outperforming existing immune therapies.
Researchers at Washington State University have discovered that a specific population of CD4-positive helper T cells initiates antitumor immunity defenses, which can enhance the effectiveness of killer cell attacks on cancer cells. This finding holds promise for improving cancer immunotherapy response rates.
A recent study published in Pharmaceutics suggests that berberine can suppress the proliferation of lung cancer cells, reduce airway inflammation, and modulate genes involved in inflammation. The researchers used liquid crystalline nanoparticles to enhance safety and effectiveness.
Research describes how breast cancer cells impair pancreatic islet function to suppress insulin production, leading to diabetes and increased tumor growth. The study identifies microRNA-122 as a key player in this process.
Researchers at the University of Chicago Medicine Comprehensive Cancer Center and the University of Amsterdam have identified a new mechanism that prompts T cell responses, including MHC-I cross-dressing. This discovery may lead to improved vaccine design and targeted cancer treatment strategies.
Researchers have found that gamma delta T cells can be trained to become extreme killers by recognizing abnormal target cells. This discovery has implications for developing novel cellular therapies to treat cancer and infectious diseases.
A Brazilian group developed a peptide called Rb4 that triggers necrosis in murine melanoma cells and inhibits the viability of human cancer cells. In mice, Rb4 reduced lung metastasis and slowed subcutaneous melanoma growth, increasing survival by 25%.
A new study applies 'Deep Visual Proteomics' to cancer cells, revealing mechanisms driving tumor development and exposing therapeutic targets. The method integrates advances from four technologies to analyze protein landscapes, providing insights into cancer vulnerabilities.
Researchers have developed a novel therapeutic strategy for treating glioblastoma using allogenic stem cells that can target and kill tumor cells. The therapy demonstrated profound efficacy in preclinical models, with 100% of mice living over 90 days after treatment.
Researchers at the Beckman Institute found a direct link between high-fat diets and heightened nitric oxide levels, which can lead to increased risk of inflammation and cancer development. The study used a molecular probe to visualize changes in the tumor microenvironment.
Researchers at Rice University have developed a theoretical framework to explain how cancers caused by multiple genetic mutations can be identified and potentially stopped. By analyzing energy landscapes of cellular transformation pathways, they found that the most dominant pathways are favored by chance.
The Center of BioModular Multi-Scale Systems for Precision Medicine develops rapid next-generation tests for human ailments like cancer and COVID-19 using saliva, urine, or blood samples. The technology has already helped patients through commercial partnerships with private firms.
A recent study analyzed a large database of bladder cancer patients and found that fewer than half had been tested for the relevant gene mutation or received erdafitinib treatment, despite its proven efficacy. The research highlights significant barriers to treatment, including obstacles in testing and education for healthcare providers.
Researchers have discovered a key role for mitochondrial proteins in controlling tumor cell growth and survival. By targeting these proteins, scientists hope to develop new therapies that can prevent or treat metastatic prostate cancer. The study's findings offer promising insights into the complex biology of cancer cells.
A recent study published in Nature Communications found that healthy developing neurons promote metastatic behaviour in neuroblastoma cells. This discovery highlights the importance of understanding the unique developmental environment within which cancers of embryonic origin form.
Breast cancer cells accumulate intracellular lipid droplets in acidic environments, leading to poor outcomes and disease progression. Targeting the acid-sensing receptor OGR1 may inhibit stress responses and cell growth.